Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIL Cells in Recurrent/Metastatic Solid Tumors
NCT05649618Phase 1Not yet recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Cell Therapies
01
Overview
Phase 1, open-label trial of autologous tumor-infiltrating lymphocytes in solid tumor, sponsored by Fujian Medical University Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Event at 24 months. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
autologous tumor-infiltrating lymphocytes
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05649618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05649618.